title: Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance.
abstract: Angiogenesis is implicated in several pathological conditions, including cancer, and in regenerative processes, including the formation of collateral blood vessels after stroke. Physiological angiogenesis is the outcome of a fine balance between the action of angiogenic growth factors (AGFs) and anti-angiogenic molecules, while pathological angiogenesis occurs when this balance is pushed toward AGFs. AGFs interact with multiple endothelial cell (EC) surface receptors inducing cell proliferation, migration and proteases upregulation. On the contrary, free or extracellular matrix-associated molecules inhibit angiogenesis by sequestering AGFs (thus hampering EC stimulation) or by interacting with specific EC receptors inducing apoptosis or decreasing responsiveness to AGFs. Thus, angiogenesis results from an intricate network of interactions among pro- and anti-angiogenic molecules, EC receptors and various modulators. All these interactions represent targets for the development of pro- or anti-angiogenic therapies. These aims call for suitable technologies to study the countless interactions occurring during neovascularization. Surface plasmon resonance (SPR) is a label-free optical technique to study biomolecular interactions in real time. It has become the golden standard technology for interaction analysis in biomedical research, including angiogenesis. From a survey of the literature it emerges that SPR has already contributed substantially to the better understanding of the neovascularization process, laying the basis for the decoding of the angiogenesis "interactome" and the identification of "hub molecules" that may represent preferential targets for an efficacious modulation of angiogenesis. Here, the still unexploited full potential of SPR is enlightened, pointing to improvements in its use for a deeper understanding of the mechanisms of neovascularization and the identification of novel anti-angiogenic drugs.
authors.affiliation: Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Italy. Electronic address: marco.rusnati@unibs.it.
authors.forename: Marco
authors.initials: M
authors.lastname: Rusnati
authors.affiliation: Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Italy. Electronic address: marco.presta@unibs.it.
authors.forename: Marco
authors.initials: M
authors.lastname: Presta
mesh_terms: D055808:Drug Discovery; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D018919:Neovascularization, Physiologic / Q000502:physiology*; D020349:Surface Plasmon Resonance
chemical_list: D036341:Intercellular Signaling Peptides and Proteins
keywords: Angiogenesis; Drug discovery; Endothelium; Interactome; Surface plasmon resonance